Christian Hampp

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. doi request reprint Cost-utility analysis of rimonabant in the treatment of obesity
    Christian Hampp
    Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:389-99. 2008
  2. ncbi request reprint Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida
    Christian Hampp
    Department Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
    J Pediatr 156:953-9, 959.e1. 2010
  3. ncbi request reprint Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study
    Almut G Winterstein
    Department of Epidemiology, University of Florida, Gainesville2Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville
    JAMA Pediatr 167:1118-24. 2013
  4. doi request reprint An algorithm to identify preterm infants in administrative claims data
    Efe Eworuke
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
    Pharmacoepidemiol Drug Saf 21:640-50. 2012
  5. doi request reprint Effectiveness of palivizumab prophylaxis in infants and children in Florida
    Almut G Winterstein
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
    Pharmacoepidemiol Drug Saf 21:53-60. 2012
  6. doi request reprint Response to respiratory synctial virus
    Christian Hampp
    South Med J 101:212-3; author reply 213-4. 2008

Collaborators

Detail Information

Publications6

  1. doi request reprint Cost-utility analysis of rimonabant in the treatment of obesity
    Christian Hampp
    Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:389-99. 2008
    ..To estimate the incremental cost-utility ratio (ICUR) of rimonabant 20 mg/day in the treatment of obesity from a third-party payer's perspective...
  2. ncbi request reprint Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida
    Christian Hampp
    Department Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
    J Pediatr 156:953-9, 959.e1. 2010
    ..To analyze adherence to guidelines to prevent respiratory syncytial virus hospitalization and to a monthly immunoprophylaxis schedule in the absence of prior authorization requirements...
  3. ncbi request reprint Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study
    Almut G Winterstein
    Department of Epidemiology, University of Florida, Gainesville2Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville
    JAMA Pediatr 167:1118-24. 2013
    ..Further studies are warranted to investigate the age-dependent risk of RSV hospitalization in other RSV risk groups...
  4. doi request reprint An algorithm to identify preterm infants in administrative claims data
    Efe Eworuke
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
    Pharmacoepidemiol Drug Saf 21:640-50. 2012
    ..To develop and validate an algorithm to identify preterm infants in the absence of birth certificates within Medicaid data...
  5. doi request reprint Effectiveness of palivizumab prophylaxis in infants and children in Florida
    Almut G Winterstein
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
    Pharmacoepidemiol Drug Saf 21:53-60. 2012
    ..This study aimed to evaluate effectiveness in a community-based sample...
  6. doi request reprint Response to respiratory synctial virus
    Christian Hampp
    South Med J 101:212-3; author reply 213-4. 2008